The Role of Antibiotics, Rifaximin versus Ciprofloxacin in Induction of Remission in Ulcerative Colitis

Abstract

Patients with ulcerative colitis (UC) get a variety of treatments, including antibiotics. The purpose of this meta-analysis of randomised controlled trials was to determine whether antibiotic medication improves the clinical symptoms of inflammatory bowel disease. A search of the Medline and Scopus databases was conducted, as well as a systematic review. Randomized controlled trials comparing rifaximin therapy to ciprofloxacin therapy were conducted. The study enrolled a total of 60 patients with ulcerative colitis. The period between the start and end of the treatment of the last unformed stool among the two categories of ulcerative colitis patients taking rifaximin or ciprofloxacin was evaluated. There was no considerate dissimilarity in two groups in regards to clinical improvement during the initial 24 hours (P =.199), failed to treat ulcerative colitis (P =.411), or microbiological fix (P =.222). Adverse events happened at a moderate and steady rate in each group. In the treatment of ulcerative colitis, rifaximin is a protected and compelling option in contrast to ciprofloxacin.